WO2007117432A3 - Methods and compositions for modulating angiogenesis and tumor growth - Google Patents

Methods and compositions for modulating angiogenesis and tumor growth Download PDF

Info

Publication number
WO2007117432A3
WO2007117432A3 PCT/US2007/008262 US2007008262W WO2007117432A3 WO 2007117432 A3 WO2007117432 A3 WO 2007117432A3 US 2007008262 W US2007008262 W US 2007008262W WO 2007117432 A3 WO2007117432 A3 WO 2007117432A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tumor growth
methods
modulating angiogenesis
modulating
Prior art date
Application number
PCT/US2007/008262
Other languages
French (fr)
Other versions
WO2007117432A2 (en
Inventor
Alisa Koch
Asif M Amin
Pawan Kumar
Olga Volpert
Original Assignee
Univ Michigan
Alisa Koch
Asif M Amin
Pawan Kumar
Olga Volpert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Alisa Koch, Asif M Amin, Pawan Kumar, Olga Volpert filed Critical Univ Michigan
Publication of WO2007117432A2 publication Critical patent/WO2007117432A2/en
Publication of WO2007117432A3 publication Critical patent/WO2007117432A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods and compositions for modulating angiogenesis and tumor growth. In particular, the present invention provides methods and compositions for modulating, studying, and treating angiogenesis and tumor growth in diseases characterized by female preponderance by inhibiting P-selectin.
PCT/US2007/008262 2006-03-30 2007-03-30 Methods and compositions for modulating angiogenesis and tumor growth WO2007117432A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78850606P 2006-03-30 2006-03-30
US60/788,506 2006-03-30

Publications (2)

Publication Number Publication Date
WO2007117432A2 WO2007117432A2 (en) 2007-10-18
WO2007117432A3 true WO2007117432A3 (en) 2008-11-13

Family

ID=38581573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008262 WO2007117432A2 (en) 2006-03-30 2007-03-30 Methods and compositions for modulating angiogenesis and tumor growth

Country Status (1)

Country Link
WO (1) WO2007117432A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201109965D0 (en) * 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
GB201112718D0 (en) * 2011-07-22 2011-09-07 Medical Res Council Methods
US11879012B2 (en) * 2018-03-02 2024-01-23 Peter GILLIES Method of modulating cell proliferation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783760B1 (en) * 1998-07-13 2004-08-31 Board Of Regents, The University Of Texas System Combined cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US20060052295A1 (en) * 2002-05-08 2006-03-09 Terman David S Intrathecal and intratumoral superantigens to treat malignant disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783760B1 (en) * 1998-07-13 2004-08-31 Board Of Regents, The University Of Texas System Combined cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US20060052295A1 (en) * 2002-05-08 2006-03-09 Terman David S Intrathecal and intratumoral superantigens to treat malignant disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BADIR ET AL.: "Serum P-selectin level during controlled ovarian hyperstimulation - a preliminar report", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 52, 2004, pages 139 - 142 *
BERTUCCI ET AL.: "Gene expression profiling of primary breast carcinomas using arrays of candidate genes", HUMAN MOLECULAR GENETICS, vol. 9, no. 20, December 2000 (2000-12-01), pages 2981 - 2991, XP002225994 *
CHEN ET AL.: "Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function", WORLD J. GASTROENTEROL., vol. 9, no. 7, 2003, pages 1607 - 1610 *
KIM ET AL.: "P-selectin deficiency attenuates tumor growth and metastasis", PNAS, vol. 95, August 1998 (1998-08-01), pages 9325 - 9330 *
TEBES ET AL.: "The genes of RNA interference, its potential clinical applications, and implications in gynecologic ancer", GYNECOLOGIC ONCOLOGY, vol. 99, 2005, pages 736 - 741 *

Also Published As

Publication number Publication date
WO2007117432A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
IN2012DN02081A (en)
WO2008089397A3 (en) Adrb2 cancer markers
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009012176A3 (en) Methods and compositions for treating brain diseases
WO2008030883A3 (en) Treatment of cancer
WO2008100384A3 (en) Activin-actriia antagonists and uses for promoting bone growth in cancer patients
WO2007093627A3 (en) Biocidal composition
WO2009011850A3 (en) Novel therapeutic compounds
WO2009158658A3 (en) Induction of flocculation in photosynthetic organisms
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
EP2418945A4 (en) Mineral salt-sulfonic acid compositions and methods of use
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2010011284A3 (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2009023710A3 (en) Xanthohumol-enriched hop extract
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2007144057A3 (en) Antimicrobial carbon
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2012017321A3 (en) Treatment for dyslipidemia
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2010034006A3 (en) The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2.
WO2007079141A3 (en) Method of identifying compounds useful to treat neuronal degenerative diseases
WO2006091544A3 (en) Methods and compositions for modulating calcium channels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754739

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754739

Country of ref document: EP

Kind code of ref document: A2